129 related articles for article (PubMed ID: 38849938)
21. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
22. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.
Sasso MS; Lollo G; Pitorre M; Solito S; Pinton L; Valpione S; Bastiat G; Mandruzzato S; Bronte V; Marigo I; Benoit JP
Biomaterials; 2016 Jul; 96():47-62. PubMed ID: 27135716
[TBL] [Abstract][Full Text] [Related]
23. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
24. Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy.
Bai L; Liu H; You R; Jiang X; Zhang T; Li Y; Shan T; Qian Z; Wang Y; Liu Y; Li C
Mol Pharm; 2024 May; 21(5):2148-2162. PubMed ID: 38536949
[TBL] [Abstract][Full Text] [Related]
25. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
Sumida K; Wakita D; Narita Y; Masuko K; Terada S; Watanabe K; Satoh T; Kitamura H; Nishimura T
Eur J Immunol; 2012 Aug; 42(8):2060-72. PubMed ID: 22653638
[TBL] [Abstract][Full Text] [Related]
26. A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells.
Zhou S; Shang Q; Ji J; Luan Y
ACS Appl Mater Interfaces; 2021 Oct; 13(40):47407-47417. PubMed ID: 34597015
[TBL] [Abstract][Full Text] [Related]
27. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer.
Singh B; Maharjan S; Pan DC; Zhao Z; Gao Y; Zhang YS; Mitragotri S
Biomaterials; 2022 Jan; 280():121302. PubMed ID: 34894584
[TBL] [Abstract][Full Text] [Related]
28. Ganoderma lucidum spores-derived particulate β-glucan treatment improves antitumor response by regulating myeloid-derived suppressor cells in triple-negative breast cancer.
Bu Y; Liu Q; Shang Y; Zhao Z; Sun H; Chen F; Ma Q; Song J; Cui L; Sun E; Luo Y; Shu L; Jing H; Tan X
Int J Biol Macromol; 2024 Jun; 270(Pt 1):131949. PubMed ID: 38749890
[TBL] [Abstract][Full Text] [Related]
29. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
30. ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.
Liu C; Qiang J; Deng Q; Xia J; Deng L; Zhou L; Wang D; He X; Liu Y; Zhao B; Lv J; Yu Z; Lei QY; Shao ZM; Zhang XY; Zhang L; Liu S
Cancer Res; 2021 Dec; 81(23):5919-5934. PubMed ID: 34580061
[TBL] [Abstract][Full Text] [Related]
31. Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors.
Qin X; He L; Feng C; Fan D; Liang W; Wang Q; Fang J
ACS Appl Mater Interfaces; 2021 Oct; 13(39):46270-46281. PubMed ID: 34550685
[TBL] [Abstract][Full Text] [Related]
32. Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone.
Zhou S; Shang Q; Wang N; Li Q; Song A; Luan Y
J Control Release; 2020 Dec; 328():617-630. PubMed ID: 32976902
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
34. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
35. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
Front Immunol; 2020; 11():613215. PubMed ID: 33679700
[TBL] [Abstract][Full Text] [Related]
36. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
37. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
38. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
39. RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment.
Mu XY; Wang RJ; Yao ZX; Zheng Z; Jiang JT; Tan MY; Sun F; Fan J; Wang X; Zheng JH; Wu K; Liu ZH
Mol Immunol; 2019 May; 109():140-148. PubMed ID: 30951933
[TBL] [Abstract][Full Text] [Related]
40. Novel mucoadhesive celecoxib-loaded cubosomal sponges: Anticancer potential and regulation of myeloid-derived suppressor cells in oral squamous cell carcinoma.
Mabrouk AA; El-Mezayen NS; Tadros MI; El-Gazayerly ON; El-Refaie WM
Eur J Pharm Biopharm; 2023 Jan; 182():62-80. PubMed ID: 36513316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
